JNJ - MindMed: Despite MDMA Setback Still Hope In Light Of Differentiating Factors

2024-06-05 11:46:27 ET

Summary

• Mind Medicine's (MindMed) results from phase 1 investigator-initiated trial, using MM-402 for the treatment of patients with Autism Spectrum Disorder, expected Q2 of 2024.
• The primary endpoint of the phase 2b MMED008 study met with statistical significance of HAM-A score over a 4-week period; Patients were given MM-120 to treat GAD.
• The global Generalized Anxiety Disorder treatment market is expected to reach $4.26 billion by 2033.
• MindMed has a backup candidate in its pipeline, MM-402, which still uses MDMA targeting for disorders, but with an improved safety profile; this would be MDMA types R[-]-MDMA, S[+]-MDMA and R/S-MDMA.

Mind Medicine (MindMed) Inc. ( MNMD ) is a biotech that should be on everyone's watch list. The reason why I state this is that it has been able to make substantial improvements in the MDMA treatment space against certain types of disorders....

For further details see: